ultra-deep targeted sequencing for personalized bc care

[Hopeful]

http://breast-cancer-research.com/content/pdf/bcr3584.pdf

At page 13:

Looking at somatic mutations and amplification, we would have proposed the use of Trastuzumab for 7 patients based on ERBB2 status. Notably, for one of them the ERBB2 gene is not amplified but carried an activating mutation, which would have been missed through standard Her2 testing.

Hopeful

['lizbeth]

Hopeful,

Thank you for posting this - It is very visual and may be a great learning tool for me.

@Sarah - did you notice this research is coming from California? You are correct, we are on the cutting edge of cancer :)